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Young children with fragile X syndrome (FXS) often experience anxiety, irritability, and hyperactivity related to sensory
hyperarousal. However, there are no medication recommendations with documented eﬃcacy for children under 5 years old of
age with FXS. We examined data through a chart review for 45 children with FXS, 12–50 months old, using the Mullen Scales of
Early Learning (MSEL) for baseline and longitudinal assessments. All children had clinical level of anxiety, language delays based
on MSEL scores, and similar early learning composite (ELC) scores at their first visit to our clinic. Incidence of autism spectrum
disorder (ASD) was similar in both groups. There were 11 children who were treated with sertraline, and these patients were
retrospectively compared to 34 children who were not treated with sertraline by chart review. The baseline assessments were done
at ages ranging from 18 to 44 months (mean 26.9, SD 7.99) and from 12 to 50 months (mean 29.94, SD 8.64) for treated and not
treated groups, respectively. Mean rate of improvement in both expressive and receptive language development was significantly
higher in the group who was treated with sertraline (P < 0.0001 and P = 0.0071, resp.). This data supports the need for a controlled
trial of sertraline treatment in young children with FXS.
1. Introduction
Fragile X syndrome (FXS) is a single gene disorder caused
by mutation in the fragile X mental retardation 1 (FMR1)
gene located at Xq27.3. The full mutation of CGG repeat
expansion (>200 repeats) in the 5′ untranslated region
(UTR) region leads to transcriptional silencing of the gene
and a lack of fragile X mental retardation protein (FMRP)
resulting in FXS [1]. FXS is the most common inherited form
of intellectual impairment known, and it is characterized by
a broad spectrum of cognitive, behavioral, and emotional
impairment. The level of cognitive impairment ranges from
borderline to severe intellectual disability (ID), and it
correlates with the level of FMRP in blood [2, 3]. The full
mutation allele frequency of FXS is about 1 in 4,000 in the
general population [4, 5].
FMRP, an RNA binding, stabilizing, and transporter
protein, is essential for synaptogenesis and the maturation
and pruning processes of dendrite spines during develop-
ment and throughout life [6–8]. FMRP is also a regulator
of translation, typically through suppression, so the lack
of FMRP leads to excessive synthesis of proteins [9] and
2 Autism Research and Treatment
synaptic dysfunction throughout the brain [10]. FMRP is
functionally linked to perhaps hundreds of mRNAs [11], so
that its absence disrupts the neurochemical foundation of
learning, memories, and behavior [12].
Behavioral and emotional impairment in FXS includes
shyness, social avoidance, anxiety, tactile defensiveness,
mood instability, irritability, impulsiveness, hyperactivity,
aggression, self-injurious behavior, autism spectrum disor-
ders (ASD), and aggression [13–18]. Many of these behaviors
interfere with social interaction thereby further impacting
language and learning [19]. Language development has a
significant impact on overall cognitive abilities in FXS [20]
and is also a critical domain to predict comorbid autism in
children with FXS [21–23]. Receptive language is relatively
less aﬀected than expressive language in young children with
FXS [20]. Likewise, the degree of communication deficit
has an impact on the level of anxiety for children with
autistic disorders [24]. Approximately, 30% of individuals
with FXS have autistic disorder and another 30% have
pervasive developmental disorder not otherwise specified
(PDD NOS) [25]. These categories will be jointly referred to
ASD throughout this paper. Those with FXS and comorbid
autism have been shown to have lower cognitive, adaptive,
motor, and language abilities compared to those with FXS
without autism [21, 26–29].
Selective serotonin reuptake inhibitors (SSRIs) have been
widely used to treat anxiety, depression, and obsessive com-
pulsive disorder (OCD). One such SSRI, sertraline, has been
approved by the Food and Drug Administration (FDA) as a
treatment for OCD in children (age 6–17 years old). Another
SSRI, fluoxetine, has been approved by the FDA as an
antidepressant treatment in children over 7 years old. Over
the past two decades, SSRIs have been increasingly prescribed
to children with ASD. In an open trial of fluoxetine, improve-
ments were seen in social, communication, and cognitive
domains in 129 children (2–8 years old) with autism [30]. In
1997, Steingard et al. published a case series of nine children
with autism (6–12 years) treated with a low dose of sertraline
(25–50mg daily). Eighty-nine percent showed significant
improvement in anxiety, irritability, and transition-induced
behavioral deterioration [31]. By contrast, a controlled trial
showed that another SSRI, citalopram, was not eﬀective in
children with autism aged 5–17 years old [32]. Although
sertraline has been shown to have some beneficial eﬀects in
children with ASD with relatively few adverse eﬀects [33], it
is not currently FDA approved to treat ASD in children.
Serotonin is known to enhance synaptic modulation and
refinement [34]. During the period of peak synaptogenesis
in early brain development (the first 5 years of life), there
is evidence in children with ASD that brain synthesis of
serotonin is reduced [35–37]. Serotonin can upregulate neu-
rogenesis in the animal and human hippocampus [38–41]. A
recent report of the use of fluoxetine, in the mouse model of
Down syndrome demonstrated enhanced neurogenesis and
restoration of the expression of 5-hydroxytriptamine 1A (5-
HT1A) receptor when used after birth. In this study, the levels
of brain-derived neurotropic factor (BDNF) were increased
with enhancement in cognition [42]. This is the first paper
of an SSRI-enhancing neurogenesis in early development
completed with recovery of memory performance in an
animal model of a neurodevelopmental disorder. Increased
BDNF levels in the CNS can also have beneficial eﬀects in
FXS, including reversal of the dendritic spine abnormalities
in FXS [43, 44]. The finding of an alteration of serotonin
synthesis in children with ASD and the important role of
serotonin in postnatal brain development and neurogenesis
suggest the need for exploring the use of an SSRI in early
childhood to reverse these deficits in those with ID or ASD
[37].
In our clinical practice, we currently often use sertraline,
an SSRI, to treat anxiety in young children with FXS and
we hypothesize that this treatment may also help language
development in these children. Therefore, we report here a
chart review carried out retrospectively, comparing young
children with FXS treated with sertraline compared to those
not treated with sertraline who were age matched with
a similar baseline developmental level. We compared the
developmental language testing that was carried out in the
past in both groups.
2. Method
2.1. Subjects/Participants. We conducted an observational
retrospective analysis of the longitudinal changes in the
Mullen Scales of Early Learning (MSEL) scores over time in
45 young children with FXS aged 12–50 months (42 male,
3 female), seen between the years of 2004 and 2011. Partici-
pants were children diagnosed with FXS and seen both clin-
ically and for research through a variety of studies including
those diagnosed at the time of birth, those diagnosed through
prenatal studies in a known carrier, and young children
with developmental delay who were diagnosed with FXS. All
families signed an informed consent for research studies that
included genetic assessment of FMR1 and for developmental
testing in the past, although all were also followed clinically
through the Fragile X treatment and Research Center at
the MIND Institute at the University of California at Davis
Medical Center. All children were confirmed to have the full
mutation with or without mosaicism by molecular testing.
Language delay and comorbid ASD were documented by
the Autism Diagnostic Observation Schedule (ADOS) [45],
the Autism Diagnostic Interview, Revised (ADI-R) [46], and
the Diagnostic and Statistical Manual of mental disorders,
fourth edition (DSM-IV) [47, 48]. In our chart review, we
found 11 children who were assessed at baseline and then
with followup assessments after sertraline treatment that was
prescribed clinically to treat anxiety and social deficits, and
another 34 children who were not taking sertraline and were
similarly assessed over time. In our chart review, sertraline
was administered as early as 18 months in this retrospective
study.
The control group represented children with FXS who
were not treated with sertraline (OFF sertraline), who
were matched on age, language delay, MSEL early learning
composit (ELC), and ASD at baseline. There were a variety
of reasons that the control group did not receive sertraline
clinically: (1) they were seen at the MIND Institute before
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Table 1: Participant age, total length of observation (followup) times in months, and time to first followup by study group (ON/OFF ser-
traline).
Variable (month) Group Number Mean SD Min Median Max
Age in months at baseline among all subjects
ON sertraline 11 26.91 7.99 18.0 23 44
OFF sertraline 34 29.94 8.64 12.0 29.5 50
Age at baseline among subjects with at least 1 follow-up
ON sertraline 11 26.91 7.99 18.0 23 44
OFF sertraline 17 25.41 7.23 12.0 25 37
Time to first followup visit
ON sertraline 11 11.73 6.97 4.1 9 24
OFF sertraline 17 19.41 9.15 2.0 22 34
Total length of followup time
ON sertraline 11 18.55 8.61 4.1 17 34
OFF sertraline 17 24.65 6.24 14.0 24 37
sertraline was recommended clinically at such a young
age or (2) parental refusal, did not want to treat their
children with medication at a young age or (3) adverse side
eﬀects and subsequent discontinuation within 1 month of
treatment onset (n = 2). The treatment dose of sertraline
ranged from 2.5mg to 12.5mg/day for at least a three-
month period. Dosage typically began at 2.5mg/day and
was increased as tolerated (mean 5.85mg/day, SD 2.51).
Higher doses typically lead to hyperarousal, more tantrums,
irritability, and/or aggression. Individuals in both groups
received similar early interventions, that is, 1 or 2 times/week
until preschool at which time daily special education was
received including speech therapy and occupational therapy
through their community during the followup time. Table 1
summarizes age at baseline, time to first followup visit, and
total length of followup by group.
2.2. Instruments. The MSEL has been used to measure
children’s developmental status from birth to 69 months of
age [49]. The MSEL includes the gross motor (GM), fine
motor (FM), visual reception (VR), receptive language (RL),
and expressive language (EL) domains to achieve a complete
and diﬀerentiated view of development in young children.
Age equivalent scores were generated from each domain,
and an Early Learning Composite (ELC) standard score was
computed based on raw scores of the five domains.
ASD was diagnosed by standardized measures including
the ADOS [45], the ADI-R [46], and the DSM-IV [47],
followed by a multidisciplinary team consensus of ASD
diagnosis, and this was documented in our charts [25].
2.3. Data Analysis. To assess the diﬀerential rate of change
(improvement) in the MSEL, linear mixed eﬀects models
were used with group (ON or OFF sertraline as defined
earlier), age/time of measurement (in months), and group
by time interaction with primary outcomes as expressive
and receptive language score. Here, we report results for raw
scores (as results based on the corresponding age equivalent
expressive and receptive scores were similar). We employed a
significance level of 0.05, and analyses were performed using
SAS version 9.2. Predicted expressive and receptive language
scores based on the fitted mixed model are provided at 20
months (about baseline) and at 40 months (corresponding
to ∼20 months after baseline).
3. Results
We examined MSEL expressive and receptive language over
time in 45 children whose age at baseline assessment ranged
from 12 to 50 months of age and who had language
delays and similar MSEL Early Learning Composite Scores
(Table 2). This includes 11 children who received sertraline
after a baseline assessment and 34 children who were not
on sertraline throughout the duration of the observation
(followup) period.
The incidence of ASD was similar in both groups (72.7%,
or 8/11, and 79% or 27/34, resp.). The time from baseline
to first followup for the ON sertraline group (mean 11.7
months, SD 7.0 months) was significantly shorter than
that of OFF sertraline group (mean 19.4 months, SD 9.2
months, P = 0.0255). The total length of followup time
for the ON sertraline group (mean 18.6, SD 8.61) was
significantly shorter than that of OFF sertraline group (mean
24.7 months, SD 6.2 months, P = 0.039). For the 11 children
in the ON sertraline group, five had one followup visit, three
had three followup visits, and the remaining three each had
four, five, and six followup visits. Among the 34 children who
were not on sertraline, 12 had one followup visit, three had
3 followup visits, and two had 4 followup visits; 17 had only
baseline measurements.
As expected, language improvement was observed for all
children over time (Figure 1). However, the rate of language
improvement was significantly higher for children who were
on sertraline after baseline compared to children who were
not on sertraline through the observation period with respect
to both expressive language (P < 0.0001) and receptive
language (P = 0.0071). See Table 3 for details. For expressive
language, the model-based mean MSEL score at age 20
months (about baseline) was similar for the ON sertraline
group (mean 9.72, SE 1.89) and OFF sertraline group (mean
9.09, SE 1.20), but average scores at age 40 months between
the groups were significantly diﬀerent: mean 22.36 (SE 1.49)
compared to mean 13.59 (SE 0.91), respectively. This similar
pattern of improvement was also observed for receptive
language (see Table 3 and Figure 1 for details).
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Table 2: Participants baseline MSEL receptive, expressive languages, and early learning composite score.
Group Receptive raw
Expressive
raw
Receptive T
score
Expressive T
score
Receptive age
equivalent (mo.)
Expressive age
equivalent (mo.)
ELC
ON sertraline
Mean 14.4 11.9 20.2 20.1 10.9 10.2 50.0
STD 5.5 4.5 4.9 5.6 5.1 4.6 14.2
OFF sertraline
Mean 13.9 11.5 20.7 20.6 12.1 10.8 50.4
STD 4.6 5.0 4.1 4.4 4.8 5.6 10.4
MSEL: Mullen Scale of Early Learning; STD: standard deviation; ELC: early learning composite.
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Figure 1: Expressive (a) and receptive language (b) trajectories over time for children on sertraline after baseline and children not on ser-
traline throughout the duration of the observation period.
4. Discussion
Assessment of the developmental trajectory in young chil-
dren is very challenging, but it is necessary for a better
understanding of developmental changes over time and can
provide important information regarding eﬀects of early
treatment with sertraline in combination with early develop-
mental interventions. From our retrospective chart review,
we report here a better rate of improvement in language
development over time for children with FXS who were
treated with sertraline compared to children of similar ages
and who did not receive sertraline treatment. Although
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Table 3: Change in expressive and receptive language (raw) MSEL scores.
Average score at age 20 months Average score, age at 40 months
ON sertraline OFF sertraline ON sertraline OFF sertraline
Outcome Variable Coeﬃcient SE1 P value Estimate2 SE Estimate SE Estimate SE Estimate SE
Expressive
language
Intercept 4.594 1.9994 0.0265 9.72 1.89 9.09 1.20 22.36 1.49 13.59 0.91
Group
(sertraline)
−7.5049 3.7628 0.0525
Age 0.2249 0.04961 <.0001
Age× group 0.4067 0.0948 <.0001
Receptive
language
Intercept 6.4653 1.837 0.001 15.32 1.81 11.47 1.13 25.14 1.45 16.48 0.89
Group
(sertraline)
−0.9751 3.4644 0.7797
Age 0.2504 0.04488 <.0001
Age× group 0.2408 0.08528 0.0071
1
SE : etandard error.
2Model-based estimate of mean expressive/receptive language score.
this is an observational retrospective study which is not a
treatment trial, the results suggest the need for a controlled
trial of sertraline in young children with FXS. These data
reflect our clinical experience with sertraline in treating
young children with FXS, and we have seen improvements
in anxiety, irritability, and socialization in addition to the
language improvements noted in the MSEL assessments.
Typically, the developmental trajectory in children with
FXS is approximately 50% of the normal rate and expressive
language is even lower [50]. A recent study reports that
developmental delays in receptive and expressive language
domains were evident by 9 month of age in children with
FXS [51]. Language is an important domain because it most
strongly correlates with intellectual ability. It is also the one
of the main modalities through which a child relates to his
environment, and it is an important conduit for social and
emotional enrichment and stimulation from environment
[20, 22]. Anxiety can interfere with social interaction, and it
can also impair language development particularly in those
with FXS [17, 24]. Early use of sertraline has been recently
used clinically to improve both anxiety and social interaction
in young children with FXS because of the emerging data
regarding the use of an SSRI in young children with autism
[30, 31, 36]. Because the clinical use of sertraline was not part
of a study, we did not have followup measures of anxiety but
instead we have only our routine MSEL testing that is carried
out on all young children with FXS that we see clinically or
for research.
In our clinical experience, fluoxetine can often be too
activating; however, sertraline in low dose (2.5 to 5mg daily)
is less activating and usually well tolerated in young children
with FXS. Sertraline has minimal adverse eﬀects compared
to other SSRIs, and it also has minimal interference with the
metabolism of other medications [52, 53].
Of concern is the recent report regarding the use of
citalopram (another SSRI) in autism [32]. This treatment did
not demonstrate eﬃcacy, but the age of the children treated
was 5 to 17 years old [32]. Perhaps the eﬀect that we see here
in FXS is only apparent in young children under 5 years of
age because this is a period of significant synaptogenesis.
Sensory integration (SI) problems, characterized by
inappropriate reactions to stimuli, have been reported in
infants at 9–12 month of age with FXS [54]. At older ages,
SI problems manifest as a variety of symptoms including
tactile defensiveness, anxiety, hyperactivity, repetitive speech,
hand flapping, rocking, and impulsivity [18, 29, 55–57].
We noted that treatment with sertraline often improved the
anxiety and irritability of young children with FXS [31] and
perhaps this improvement indirectly aﬀected the language
development of children with FXS. Alternatively, it is possible
that sertraline may have a direct eﬀect on the language areas
of the brain through enhanced connectivity or neurogenesis.
It is essential for any pharmacological intervention to also
be combined with early intervention from an educational
standpoint. The eﬀects of environmental stimulation in
improving synaptic connections have been well demon-
strated in FXS. Meredith and colleagues described that spike-
timing-dependent long-term potentiation (STD LTP) in the
prefrontal cortex, which is involved in higher cognitive
function, was restored to wild-type (WT) level by an
environmental enrichment in the Fmr1 KO mouse [58]. In
another study of the FMR1-KOmouse, an enriched environ-
ment rescued the abnormalities of the dendritic spines [59].
Enriched environments have antidepressant-like activity in
animals and stimulate neurogenesis in the hippocampus
[60]. All of the children who took part in this study received
early intervention including speech and language therapy,
occupational therapy (OT), and/or physical therapy (PT).
However, the study here suggests that the use of sertraline
can have a further beneficial eﬀect at least with the trajectory
of language development compared to those not treated with
sertraline.
The use of targeted treatments that will reverse the
neurobiological consequences of the FMRP deficit such as
metabotropic glutamate receptor 5 (mGluR5) antagonists
and gamma-aminobutyric acid (GABA) agonists will likely
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be helpful for young children in the future, but these
medications are not currently available to prescribe to young
children [48, 61]. Sertraline is currently available, and further
studies including a controlled trial are warranted in young
children with FXS.
5. Study Limitations
This is an analysis of retrospective data obtained in a
chart review of medical records, and there are significant
limitations in such a study. There can be clinical bias in
who receives the sertraline and who does not in addition to
other potential baseline confounders associated with receipt
of treatment and with language development that were not
available in the medical records. This analysis was based on
observation data where the administration of sertraline was
not as uniform, compared to a clinical trial study. Thus,
there was variation in the start of sertraline after baseline
for the 11 subjects on sertraline. Therefore, the results
reported here should be interpreted with some caution
and studies, including randomized controlled trials with a
large number of patients so that individual diﬀerences in
developmental trajectories will be also controlled for are
needed to determine the eﬃcacy of sertraline in young
children with FXS.
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